Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
202 Clinical Updates found
Multiple myeloma cell
A Single Surviving Myeloma Cell Can Seed Accelerated Relapse

A single surviving myeloma cell can seed accelerated relapse, and more than 20 percent of nonsynonymous mutations at relapse may be induced by exposure to chemotherapy such as platinum and high-dose melphalan after autologous stem cell transplant.
Mark Souweidane continues advancing treatment for children with DIPG
Review: Our Experience with Convection Enhanced Delivery for Diffuse Intrinsic Pontine Glioma

Convection enhanced delivery, an innovative technique that directly infuses a therapeutic agent into a brain tumor through a cannula, bypassing the blood-brain barrier, is safe and feasible for treating diffuse intrinsic pontine glioma in children.
Lymphoma specialist Dr Anita Kumar with patient
Two New Clinical Trials Increase Treatment Options for Mantle Cell Lymphoma Patients

Two important clinical trials to increase treatment options for mantle cell lymphoma patients are currently recruiting patients.
Microscopic image of adenocarcinoma lung cancer cells
Alterations in Driver Genes Predict Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma

In patients with resected pancreatic ductal adenocarcinoma, alterations in KRAS and TP53 were associated with worse outcomes, whereas alterations in homologous recombination deficiency genes were associated with favorable prognoses.
Severity of COVID-19 in Patients with Lung Cancer: Not Driven by Cancer or Cancer Treatments

Our study, published recently in the Annals of Oncology, suggests that the greatest determinants of COVID-19 severity were patient features and comorbidities, such as a history of heavy smoking and chronic obstructive pulmonary disease (COPD).
T cell attacking cancer cells
CAR T Update Part 1: Learning and Opportunities in Hematologic Cancers

In our paper, published recently in the journal Expert Review of Hematology, we review the main challenges with current CD19-targeted CAR, obstacles to adopting CAR T cell therapy in solid tumors, and various strategies scientists are pursuing to overcome these issues.
https://www.mskcc.org/clinical-updates/car-update-part-1-learning-and-opportunities-hematologic
CAR T Update Part 2: Challenges and Opportunities in Solid Tumors

This CAR T Update Part 2 summarizes the unique challenges with using CARS to defeat solid tumors, and how learning from preclinical and clinical research in hematologic malignancies is informing new strategies and research efforts.
Bill Tap, Chief of MSK's Sarcoma Medical Oncology Service
Combination Immunotherapy Meets Primary Endpoint in Phase II Clinical Trial in Advanced Sarcoma

The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.
Surgery at MSK
Best Practices for Managing Cancer Surgery during the COVID-19 Pandemic

Memorial Sloan Kettering has convened a COVID-19 Operating Room Executive Committee to scrutinize all surgical cases and determine whether they were truly essential and to review needs, resources, and ICU availability.
CAR T cells attacking cancer
CAR T Cell Therapy Should Proceed During the COVID-19 Pandemic

Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite Covid-19 according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S. academic institutions.